The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Update of AMC 0101 study: A phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322).
Yoon-Koo Kang
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Heung-Moon Chang
No relevant relationships to disclose
Dae Young Zang
No relevant relationships to disclose
Tae Won Kim
No relevant relationships to disclose
Dae Hyun Yang
No relevant relationships to disclose
Se Jin Jang
No relevant relationships to disclose
Jeong Hwan Yook
No relevant relationships to disclose
Sung Tae Oh
No relevant relationships to disclose
Byung Sik Kim
No relevant relationships to disclose